Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Devon Energy Corp (DVN) vs Eli Lilly And Co (LLY) Price & Performance

Devon Energy CorpTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Devon Energy Corp vs Eli Lilly And Co — how do they compare? Devon Energy Corp trades at $45.02 (market cap $49.94B), while Eli Lilly And Co trades at $1,223.26 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 21.6× Devon Energy Corp's market cap, and Devon Energy Corp pays the higher dividend (2.82%). Which is the better fit depends on your goals.

DVNLLY
Market Cap
$49.94B$1.08T
Sector
EnergyHealth
52-Week High
$52.07$1.24K
52-Week Low
$31.74$639.43
Enterprise Value
$60.68B$1.13T
Dividend Yield
2.82%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Devon Energy Corp

Devon Energy (DVN) trades at $44.93, down 0.95% on the day, amid a bullish technical signal and strong Q2 2026 earnings that beat estimates. The company reported EPS of $1.57 versus $1.40 expected, driven by merger synergies and higher oil production. Valuation ratios remain attractive with a P/E of 9.87 and EV/EBITDA of 6.89. Recent news highlights a 33% dividend hike and accelerated debt reduction, reinforcing positive sentiment.

The outlook for DVN is positive, supported by robust free cash flow, shareholder returns, and operational execution. Key opportunities include synergy realization from the Coterra merger and a consensus price target of $61.91. Risks involve oil price volatility and integration challenges. Wall Street sentiment is strongly bullish with 71% buy ratings.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Devon Energy Corp

Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.

Read more on DVN

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY